Table 1 Baseline characteristics based on the 55 investigated SLE patients
Characteristic | |
|---|---|
Female participants, n (%) | 50 (90.9) |
Ethnicity | |
Caucasian, n (%) | 52 (94.5) |
African/African American, n (%) | 3 (5.5) |
Age (years), median (IQR) | 41.2 (30.6–50.4) |
SLE disease duration (years), median (IQR) | 7.8 (4.3–14.2) |
SLEDAI-2K, median (IQR) | 8.0 (4.0–14.0) |
C3 (g/L), median (IQR) | 0.81 (0.62–1.02) |
C4 (g/L), median (IQR) | 0.11 (0.06–0.19) |
Number of DMARDs tested until baseline*, median (IQR) | 2 (1–3) |
Number of DMARDs at baseline*, median (IQR) | 1 (0–1) |
Azathioprine, n (%) | 18 (32.7) |
Mycophenolate mofetil/sodium†, n (%) | 10 (18.2) |
Methotrexate, n (%) | 8 (14.5) |
Cyclosporine, n (%) | 2 (3.6) |
Antimalarial agents at baseline, n (%) | 41 (74.5) |
Prednisone equivalent dose at baseline (mg/day), median (IQR) | 10.0 (8.4–12.9) |
Reason for belimumab | |
Mucocutaneous manifestations, n (%) | 26 (47.3) |
Musculoskeletal manifestations, n (%) | 25 (45.5) |
Hematological manifestations, n (%) | 10 (18.2) |
Lupus nephritis, n (%) | 7 (12.7) |
Neuropsychiatric SLE, n (%) | 4 (7.3) |
Serositis, n (%) | 3 (5.5) |
Constitutional symptoms#, n (%) | 2 (3.6) |